Drug Profile
Research programme: Hsp90 heat shock protein inhibitors - Merck Serono/Merck KGaA
Alternative Names: EMD 683671; Hsp90 inhibitors - Merck Serono Research/Merck KGaALatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck KGaA; Merck Serono
- Class Indazoles; Resorcinols; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 02 Sep 2010 Preclinical development is ongoing in Germany
- 04 Sep 2008 Preclinical trials in Cancer in Germany (PO)